Eric Sharps is a seasoned expert in the biotechnology and pharmaceutical industries, boasting over 30 years of diverse experience that uniquely positions him as a thought leader in the field. As the Founder of FourSquare Partners, Eric has cultivated a robust platform for providing independent...
Eric Sharps is a seasoned expert in the biotechnology and pharmaceutical industries, boasting over 30 years of diverse experience that uniquely positions him as a thought leader in the field. As the Founder of FourSquare Partners, Eric has cultivated a robust platform for providing independent buy-side analysis, focusing on biotechnology and medical devices for institutional investors. His extensive background as an analytical protein biochemist at renowned companies such as Monsanto, Hoffmann-La Roche, and Scios has equipped him with a deep understanding of biochemistry and the intricacies of drug development.
Since 1995, Eric has honed his expertise in venture capital and public equity markets, specializing in health care investments. His analytical acumen allows him to evaluate emerging biopharmaceuticals and innovative clinical trials critically, identifying promising opportunities that align with market trends and investor interests. Key projects under his leadership at FourSquare Partners include strategic assessments of oncology-focused therapeutics and the evaluation of novel assay development techniques that enhance drug efficacy and safety.
Eric’s proficiency in navigating complex financial landscapes, combined with his scientific background, enables him to bridge the gap between cutting-edge research and investment strategy. His skills in PIPEs (Private Investment in Public Equity) and a keen understanding of the pharmaceutical industry's regulatory environment further enhance his capability to guide institutional investors toward high-potential ventures. As a thought leader, Eric continues to influence the trajectory of investments in life sciences, ensuring that FourSquare Partners remains at the forefront of the biotechnology investment landscape.
